02
Oct

Eli Lilly’s tabalumab has flopped in another Phase III program, failing to score well enough to survive as a potential new treatment for lupus–a follow-up setback to its earlier failure in rheumatoid arthritis. Lilly now plans to bury the program in its crowded graveyard of late-stage drugs.

…read more

Source: UPDATED: Eli Lilly scraps tabalumab for lupus after it flops in (another) PhIII program

    

0 No comments